DZP supports the acquisition of shares in an innovative biotechnology company

DZP's client was eCapital, a company controlled by Michał Lach, an experienced investor, founder of K2 Internet and co-founder of Audioteka and eTutor. Our experts supported the investor in concluding an agreement with NanoGroup S.A. on taking up shares for a total amount of PLN 5.1 million, at PLN 1.05 per share. The investment agreement is part of a plan to provide funding over the course of a year.

NanoGroup is planning to carry out five autotransplants in this period to confirm the effectiveness of the NanOX technology – a system for storage and perfusion of organs to extend the usefulness of organs for transplant. Implementation of the investment agreement is expected to end in early 2025.

The company in which DZP's client has invested is a biotechnology company using innovative nanotechnology solutions to meet critical medical needs. It conducts research in the areas of cancer prevention, early diagnosis and oncology rehabilitation focusing on research into human blood substitute and targeted anti-cancer therapies. The solutions NanoGroup is working on are the result of groundbreaking research carried out by Prof. Tomasz Ciach in the field of nanoparticles, whose high market potential has made it possible for the company to secure funding from leading local VC funds.

The advice provided in this project also falls under the DZP Future programme in which DZP experts support the development of innovative initiatives and the most promising enterprises with high growth potential by connecting them with a network of business angels cooperating with DZP.

The investor was advised and the transaction agreement drafted by Katarzyna Biarda, Maciej Goszczyk and Maciej Zajda from the Capital Markets & Financial Institutions Practice.